Steve Kanters

8PUBLICATIONS
15CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methodsModelling and simulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 10, 2026
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

|May 10, 2025
Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.

Frederick L Locke, Graeme Ball, Markqayne D Ray

|Jul 08, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.

James J Wu, Sally W Wade, Taha Itani

|Apr 22, 2024
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.

Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray

|Feb 01, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.

M Lia Palomba, Paola Ghione, Anik R Patel

|Jun 09, 2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.

Paola Ghione, M Lia Palomba, Anik R Patel

Pageof 2

Frequent Collaborators

2 joint publications

Eve H Limbrick-Oldfield

1 joint publications

Paola Ghione

1 joint publications

Anik R Patel

1 joint publications

Sabela Bobillo